Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database

Huaising C. Ko, Shuai Chen, Aaron M. Wieland, Menggang Yu, Andrew M. Baschnagel, Gregory K. Hartig, Paul M. Harari, Matthew E. Witek

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: There is a paucity of data regarding head and neck squamous cell carcinomas (HNSCCs) and N3 nodal disease. Methods: Retrospective analysis of patients with N3 HNSCC identified in the National Cancer Database (NCDB) was performed. Results: We identified 4867 patients with N3 HNSCC treated with primary surgery or chemoradiotherapy (CRT). Propensity-adjusted median survival was 54.2 and 44.8 months for surgery and CRT, respectively (P =.06). Oropharyngeal primary subsite demonstrated a survival advantage with surgery versus CRT with propensity-adjusted median survivals of 86.0 and 61.9 months, respectively (P <.05). Conclusion: Management of N3 HNSCC relies largely on CRT. Patients with N3 nodal disease with nonoropharyngeal primary tumors exhibit 5-year overall survival approaching 30% independent of initial treatment modality. Patients with oropharyngeal primaries exhibit improved outcomes with surgery largely influenced by the human papillomavirus (HPV)-negative subset. These data represent the most comprehensive analysis of N3 HNSCC outcomes and serves as a foundation for future research and clinical management.

Original languageEnglish (US)
Pages (from-to)2159-2170
Number of pages12
JournalHead and Neck
Volume39
Issue number11
DOIs
StatePublished - Nov 1 2017
Externally publishedYes

Fingerprint

Chemoradiotherapy
Databases
Survival
Neoplasms
Carcinoma, squamous cell of head and neck
Therapeutics

Keywords

  • head and neck cancer
  • N3 nodal staging
  • National Cancer Database
  • radiation
  • surgery

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma : Analysis of the National Cancer Database. / Ko, Huaising C.; Chen, Shuai; Wieland, Aaron M.; Yu, Menggang; Baschnagel, Andrew M.; Hartig, Gregory K.; Harari, Paul M.; Witek, Matthew E.

In: Head and Neck, Vol. 39, No. 11, 01.11.2017, p. 2159-2170.

Research output: Contribution to journalArticle

Ko, HC, Chen, S, Wieland, AM, Yu, M, Baschnagel, AM, Hartig, GK, Harari, PM & Witek, ME 2017, 'Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database', Head and Neck, vol. 39, no. 11, pp. 2159-2170. https://doi.org/10.1002/hed.24881
Ko, Huaising C. ; Chen, Shuai ; Wieland, Aaron M. ; Yu, Menggang ; Baschnagel, Andrew M. ; Hartig, Gregory K. ; Harari, Paul M. ; Witek, Matthew E. / Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma : Analysis of the National Cancer Database. In: Head and Neck. 2017 ; Vol. 39, No. 11. pp. 2159-2170.
@article{6cc822db69d54d7daddfa9529e508301,
title = "Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database",
abstract = "Background: There is a paucity of data regarding head and neck squamous cell carcinomas (HNSCCs) and N3 nodal disease. Methods: Retrospective analysis of patients with N3 HNSCC identified in the National Cancer Database (NCDB) was performed. Results: We identified 4867 patients with N3 HNSCC treated with primary surgery or chemoradiotherapy (CRT). Propensity-adjusted median survival was 54.2 and 44.8 months for surgery and CRT, respectively (P =.06). Oropharyngeal primary subsite demonstrated a survival advantage with surgery versus CRT with propensity-adjusted median survivals of 86.0 and 61.9 months, respectively (P <.05). Conclusion: Management of N3 HNSCC relies largely on CRT. Patients with N3 nodal disease with nonoropharyngeal primary tumors exhibit 5-year overall survival approaching 30{\%} independent of initial treatment modality. Patients with oropharyngeal primaries exhibit improved outcomes with surgery largely influenced by the human papillomavirus (HPV)-negative subset. These data represent the most comprehensive analysis of N3 HNSCC outcomes and serves as a foundation for future research and clinical management.",
keywords = "head and neck cancer, N3 nodal staging, National Cancer Database, radiation, surgery",
author = "Ko, {Huaising C.} and Shuai Chen and Wieland, {Aaron M.} and Menggang Yu and Baschnagel, {Andrew M.} and Hartig, {Gregory K.} and Harari, {Paul M.} and Witek, {Matthew E.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1002/hed.24881",
language = "English (US)",
volume = "39",
pages = "2159--2170",
journal = "Head and Neck Surgery",
issn = "0148-6403",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma

T2 - Analysis of the National Cancer Database

AU - Ko, Huaising C.

AU - Chen, Shuai

AU - Wieland, Aaron M.

AU - Yu, Menggang

AU - Baschnagel, Andrew M.

AU - Hartig, Gregory K.

AU - Harari, Paul M.

AU - Witek, Matthew E.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background: There is a paucity of data regarding head and neck squamous cell carcinomas (HNSCCs) and N3 nodal disease. Methods: Retrospective analysis of patients with N3 HNSCC identified in the National Cancer Database (NCDB) was performed. Results: We identified 4867 patients with N3 HNSCC treated with primary surgery or chemoradiotherapy (CRT). Propensity-adjusted median survival was 54.2 and 44.8 months for surgery and CRT, respectively (P =.06). Oropharyngeal primary subsite demonstrated a survival advantage with surgery versus CRT with propensity-adjusted median survivals of 86.0 and 61.9 months, respectively (P <.05). Conclusion: Management of N3 HNSCC relies largely on CRT. Patients with N3 nodal disease with nonoropharyngeal primary tumors exhibit 5-year overall survival approaching 30% independent of initial treatment modality. Patients with oropharyngeal primaries exhibit improved outcomes with surgery largely influenced by the human papillomavirus (HPV)-negative subset. These data represent the most comprehensive analysis of N3 HNSCC outcomes and serves as a foundation for future research and clinical management.

AB - Background: There is a paucity of data regarding head and neck squamous cell carcinomas (HNSCCs) and N3 nodal disease. Methods: Retrospective analysis of patients with N3 HNSCC identified in the National Cancer Database (NCDB) was performed. Results: We identified 4867 patients with N3 HNSCC treated with primary surgery or chemoradiotherapy (CRT). Propensity-adjusted median survival was 54.2 and 44.8 months for surgery and CRT, respectively (P =.06). Oropharyngeal primary subsite demonstrated a survival advantage with surgery versus CRT with propensity-adjusted median survivals of 86.0 and 61.9 months, respectively (P <.05). Conclusion: Management of N3 HNSCC relies largely on CRT. Patients with N3 nodal disease with nonoropharyngeal primary tumors exhibit 5-year overall survival approaching 30% independent of initial treatment modality. Patients with oropharyngeal primaries exhibit improved outcomes with surgery largely influenced by the human papillomavirus (HPV)-negative subset. These data represent the most comprehensive analysis of N3 HNSCC outcomes and serves as a foundation for future research and clinical management.

KW - head and neck cancer

KW - N3 nodal staging

KW - National Cancer Database

KW - radiation

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85031704271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031704271&partnerID=8YFLogxK

U2 - 10.1002/hed.24881

DO - 10.1002/hed.24881

M3 - Article

C2 - 28737019

AN - SCOPUS:85031704271

VL - 39

SP - 2159

EP - 2170

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 0148-6403

IS - 11

ER -